Thomas G. Gross, MD, PhD

Medical School:

University of Nebraska   MD   05/07/1988

Internship:

University of Nebraska Medical Center   06/29/1989

Residency:

University of Nebraska Medical Center   06/29/1991

Fellowship:

University of Minnesota Hospitals and Clinics   08/31/1993

Section:

Specialty:

Pediatric Hematology Oncology, Certified  
Pediatrics  

Gender:

Male

Languages Spoken:

English

Date of Appointment at
Children's Hospital:

11/15/2002

Office Practice Information:

• Accepts patients 0-18
• Accepts patients 18 years or older
• Accepts Medicaid
• Requires a written physician referral
• This office is wheelchair accessible

Academic Title:

Associate Professor of Pediatrics

Clinical, Teaching & Research Interests*:

Thomas G. Gross, MD, PhD, is the Chief of the Section of Hematology/Oncology/Blood and Marrow Transplant (BMT) at Nationwide Children’s Hospital, a member of the Center of Childhood Cancer Research at The Research Institute at Nationwide Children’s Hospital and an Associate Professor of Pediatrics at The Ohio State University College of Medicine. His clinical and research interests are pediatric BMT and lymphoma, in particular the treatment of cancers in immunocompromised patients, such as post-transplant lymphoproliferative disease (PTLD). He is an active clinical researcher through the Pediatric Oncology and Viral Oncology Program at the National Cancer Institute designated Ohio State University Comprehensive Cancer Center (OSUCCC) and numerous cooperative clinical trials groups. He serves in leadership positions at OSUCCC, including serving on the Institutional Review Board and Clinical Research Scientific Council. He is the Principal Investigator for a PTLD clinical trial in the Children’s Oncology Group (COG), and is the Chair of the NHL Disease and Scientific Chairs Committees, and is a member of the Scientific Council and Executive Committee in COG. Dr. Gross serves as an Associate Editor for Pediatric Transplantation and Advances in Hematology, as well as being on the Editorial Board for Pediatric Blood and Cancer, the Pediatric Cancer Statement of the Physician Data Query at the National Cancer Institute. He is on the Board of Trustees for the National Childhood Cancer Foundation and on the Board of Directors of the Israel Penn International Transplant Tumor Registry.

Publications*:

Gross TG. Post-transplant lymphoproliferative disease (PTLD) in children following solid organ transplantation (SOT) and rituximab – final answer?(editorial commentary). Pediatric Transplantation 11: 575-7, 2007.

Gross TG, Termuhlen AM. Pediatric non-Hodgkin’s lymphoma. Current
Oncology Report 9: 459-465, 2007.

Awards and Honors*:

Listed, Best Doctors in America

Presentations and
Teaching Activities*:

Mobilization of PML-RARA negative Peripheral Blood Stem Cells and Autologous Peripheral Blood Stem Cell Transplant in Pediatric Patients with relapsed Acute Promyelocytic Leukemia, Poster Presentation, American Society of Blood and Marrow Transplantation, Keystone, Colorado, February 2007

Post-transplant Cancer Improving Long-Term Outcomes for Pediatric Liver Transplantation: A Clinical Research Workshop, National Institutes of Health, Bethesda, Maryland, February 2007

Malignancies in Children Following Solid Organ Transplantation, 3rd Congress of International Pediatric Transplantations Association (IPTA), Cancun, Mexico, March 2007

Pathophysiology of Immunosuppression Associated Malignancies: EBV Associated Lymphoproliferative Disease as a Model, 68th Annual Meeting of Society for Investigative Dermatology, Los Angeles, California, May 2007

Post-Transplant Lymphoproliferative Disorder (PTLD): Update on Therapeutic Options, Annual American Society of Pediatric Nephrology (ASPN), Toronto, Canada, May 2007

Outcome of Childhood Cancer – How Do We Get from Good to Great?, 15th Annual Helen DeVos Distinguished Lecture in Pediatric Oncology, Grand Rapids, Michigan, August 2007

Research Funding*:

The Combination of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults with CD20 Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplant (SOT), National Cancer Institute

Consultant, SCCOR in Pediatric Heart Development and Disease. Optimizing Outcome after Pediatric Heart Transplantation, NHLBI, Principal Investigator: Steven Webber, MD (Univ. of Pittsburgh)

COG Non-Hodgkin Lymphoma Disease Committee Chair, National Cancer Institute

Consultant, Real-time Minimal Residual Disease Assay of Pediatric B-Cell Non-Hodgkin Lymphoma, National Cancer Institute, Principal Investigator: Bruce Shiramizu, MD

*Physician publications, awards and honors, and presentations and teaching activities represent work completed in 2008 only.